{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T03:07:41Z","timestamp":1782875261849,"version":"3.54.5"},"reference-count":43,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Respir Crit Care Med"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pertussis, a highly contagious respiratory disease, is preventable with vaccine. Two types of vaccines are used around the world: whole-cell pertussis vaccines (wP), which contain inactivated bacterial suspensions are difficult to produce and induce some side effects, and acellular pertussis vaccines (aP), which contain one to five purified bacterial antigens, chemically or genetically detoxified. Both the vaccines succeeded in massively decreasing child deaths caused by pertussis. However, irrespective of vaccination, the disease is still endemic around the world, and cycles of pertussis are still observed every 3 to 5 years in both wP- or aP-vaccinated regions. The interval between each cycle, and the intensity and incidence of the disease during these cycles vary. The first challenge ahead is to rapidly increase vaccine coverage by vaccinating infants on time, introducing regular vaccine boosters throughout life, and vaccinating pregnant women. The second challenge is to introduce an effective disease surveillance such as a pediatric hospital surveillance, allowing an estimation of the incidence of severe disease in the pediatric population, and\/or a sentinel surveillance, allowing to detect changes in the incidence of the disease in the population. All surveillance systems require a functional network of physicians in the country aware of the clinical forms of the disease in children, adolescents, adults, and seniors. Surveillance is required to adapt vaccine strategies according to the vaccine type and to follow the evolution of the agents of the disease. The third challenge is to pursue research to improve these vaccines. However, before changing vaccines once again, an evaluation of the exact consequences of aP or wP vaccines under specific vaccine strategies needs to be carefully carried out.<\/jats:p>","DOI":"10.1055\/a-2592-0735","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T22:49:28Z","timestamp":1749250168000},"page":"014-019","source":"Crossref","is-referenced-by-count":4,"title":["Pertussis Vaccination: The Challenges Ahead"],"prefix":"10.1055","volume":"46","author":[{"given":"Nicole","family":"Guiso","sequence":"additional","affiliation":[{"name":"Independent Medical Expert Consulting Services Inc, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl Heinz Wirsing von","family":"Koenig","sequence":"additional","affiliation":[{"name":"Independent eMedical Expert Consulting, Krefeld, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"issue":"12","key":"ref1","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1093\/cid\/cis302","article-title":"Clinical definitions of pertussis: summary of a global pertussis initiative roundtable meeting, February 2011","volume":"54","author":"J D Cherry","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"11","key":"ref2","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/cid\/cis627","article-title":"Pertussis in older adults: prospective study of risk factors and morbidity","volume":"55","author":"B C Liu","year":"2012","journal-title":"Clin Infect Dis"},{"key":"ref3","first-page":"731","article-title":"Le microbe de la coqueluche","volume":"20","author":"J Gengou O Bordet","year":"1906","journal-title":"Ann Inst Pasteur (Paris)"},{"issue":"06","key":"ref4","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1128\/jb.35.6.561-572.1938","article-title":"Bacillus para-pertussis: a species resembling both Bacillus pertussis and Bacillus bronchisepticus but identical with neither","volume":"35","author":"G Eldering","year":"1938","journal-title":"J Bacteriol"},{"issue":"12","key":"ref5","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/S1473-3099(15)00292-3","article-title":"Emergence of whooping cough: notes from three early epidemics in Persia","volume":"15","author":"A Aslanabadi","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"ref6","volume-title":"Whooping Cough","author":"J H Lapin","year":"1943"},{"issue":"02","key":"ref7","first-page":"e01074","article-title":"Global population structure and evolution of Bordetella pertussis and their relationship with vaccination","volume":"5","author":"M J Bart","year":"2014","journal-title":"MBio"},{"issue":"03","key":"ref8","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1093\/infdis\/161.3.581","article-title":"Pathogenesis in Bordetella species","volume":"161","author":"P Novotny","year":"1990","journal-title":"J Infect Dis"},{"issue":"02","key":"ref9","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/cid\/ciy889","article-title":"Severe pertussis infections in the United States, 2011\u20132015","volume":"69","author":"S A Mbayei","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"42","key":"ref10","doi-asserted-by":"crossref","first-page":"5647","DOI":"10.1016\/j.vaccine.2015.08.068","article-title":"Risk factors for pertussis hospitalizations in Australians aged 45 years and over: a population based nested case-control study","volume":"33","author":"S Karki","year":"2015","journal-title":"Vaccine"},{"issue":"11","key":"ref12","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.3390\/antibiotics11111570","article-title":"Macrolide resistance in Bordetella pertussis: current situation and future challenges","volume":"11","author":"L Ivaska","year":"2022","journal-title":"Antibiotics (Basel)"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10096-012-1718-3","article-title":"Insertion sequences shared by Bordetella species and implications for the biological diagnosis of pertussis syndrome","volume":"32","author":"A Tizolova","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"10","key":"ref14","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3201\/eid1910.130345","article-title":"Recurrent Bordetella holmesii bacteremia and nasal carriage in a patient receiving rituximab","volume":"19","author":"L B Nguyen","year":"2013","journal-title":"Emerg Infect Dis"},{"issue":"03","key":"ref15","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s10096-010-1104-y","article-title":"What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories","volume":"30","author":"N Guiso","year":"2011","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"05","key":"ref16","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.vaccine.2019.11.022","article-title":"Pertussis vaccines: the first hundred years","volume":"38","author":"N Guiso","year":"2020","journal-title":"Vaccine"},{"issue":"05","key":"ref17","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/00006454-199805000-00013","article-title":"Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination","volume":"17","author":"S Baron","year":"1998","journal-title":"Pediatr Infect Dis J"},{"issue":"06","key":"ref18","first-page":"476","article-title":"S\u00e9rodiagnostic et variabilit\u00e9 des microbes suivant le milieu de culture","volume":"24","author":"J Bordet","year":"1910","journal-title":"Ann Inst Pasteur (Paris)"},{"issue":"02","key":"ref19","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/00006454-198702000-00001","article-title":"The return of pertussis","volume":"6","author":"J W Bass","year":"1987","journal-title":"Pediatr Infect Dis J"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1097\/01.inf.0000160920.75623.a3","article-title":"Pertussis immunization in the global pertussis initiative European region: recommended strategies and implementation considerations","volume":"24","author":"C H Wirsing von K\u00f6nig","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1097\/01.inf.0000160914.59160.41","article-title":"Duration of immunity against pertussis after natural infection or vaccination","volume":"24","author":"A M Wendelboe","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"ref22","volume-title":"Pertussis vaccines","author":"K M Edwards","year":"2022","edition":"8th ed."},{"issue":"15","key":"ref23","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1056\/NEJMoa050824","article-title":"Efficacy of an acellular pertussis vaccine among adolescents and adults","volume":"353","author":"J I Ward","year":"2005","journal-title":"N Engl J Med"},{"issue":"07","key":"ref24","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/infdis\/jiu001","article-title":"Changing pertussis epidemiology: everything old is new again","volume":"209","author":"T A Clark","year":"2014","journal-title":"J Infect Dis"},{"issue":"S 04","key":"ref25","doi-asserted-by":"crossref","first-page":"S236","DOI":"10.1093\/cid\/ciw559","article-title":"Sustained effectiveness of the maternal pertussis immunization program in England 3 years following introduction","volume":"63","author":"G Amirthalingam","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"04","key":"ref26","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamapediatrics.2022.5689","volume":"177","author":"T H Skoff","year":"2023","journal-title":"JAMA Pediatr"},{"issue":"07","key":"ref29","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1080\/14787210.2016.1190272","article-title":"Surveillance of pertussis: methods and implementation","volume":"14","author":"N Guiso","year":"2016","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.eclinm.2019.02.010","article-title":"Pertussis: point-of-care testing in the making","volume":"8","author":"C H Wirsing von Koenig","year":"2019","journal-title":"EClinicalMedicine"},{"issue":"02","key":"ref31","doi-asserted-by":"crossref","first-page":"116239","DOI":"10.1016\/j.diagmicrobio.2024.116239","article-title":"Microfluidic point-of-care testing for the detection of Bordetella pertussis: a mini-review","volume":"109","author":"\u00c7 Y\u0131lmaz \u00c7olak","year":"2024","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"01","key":"ref32","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/emph\/eoac028","article-title":"Can vaccines control bacterial virulence and pathogenicity? Bordetella pertussis: the advantage of fitness over virulence","volume":"10","author":"N Guiso","year":"2022","journal-title":"Evol Med Public Health"},{"issue":"09","key":"ref33","doi-asserted-by":"crossref","first-page":"E340","DOI":"10.1111\/j.1469-0691.2012.03925.x","article-title":"Evolution of French Bordetella pertussis and Bordetella parapertussis isolates: increase of Bordetellae not expressing pertactin","volume":"18","author":"N Hegerle","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"43","key":"ref34","doi-asserted-by":"crossref","first-page":"6034","DOI":"10.1016\/j.vaccine.2009.07.074","article-title":"First report and detailed characterization of B. pertussis isolates not expressing Pertussis Toxin or Pertactin","volume":"27","author":"V Bouchez","year":"2009","journal-title":"Vaccine"},{"issue":"07","key":"ref35","doi-asserted-by":"crossref","first-page":"1700832","DOI":"10.2807\/1560-7917.ES.2019.24.7.1700832","article-title":"Pertactin-deficient Bordetella pertussis isolates: evidence of increased circulation in Europe, 1998 to 2015","volume":"24","author":"A M Barkoff","year":"2019","journal-title":"Euro Surveill"},{"issue":"24","key":"ref38","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1016\/j.vaccine.2018.03.049","article-title":"Challenges for the registration of vaccines in emerging countries: differences in dossier requirements, application and evaluation processes","volume":"36","author":"N Dellepiane","year":"2018","journal-title":"Vaccine"},{"issue":"01","key":"ref39","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.imj.2022.12.002","article-title":"Coverage rates for diphtheria, tetanus, poliomyelitis, and pertussis age-specific booster recommendations in France: 2018 update of the real-world cohort analysis","volume":"2","author":"R Verdier","year":"2022","journal-title":"Infect Med (Beijing)"},{"issue":"03","key":"ref40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.ss7003a1","article-title":"Surveillance of vaccination coverage among adult populations\u2014United States, 2018","volume":"70","author":"P J Lu","year":"2021","journal-title":"MMWR Surveill Summ"},{"issue":"40","key":"ref42","doi-asserted-by":"crossref","first-page":"6007","DOI":"10.1016\/j.vaccine.2018.08.022","article-title":"Comparison of adverse events following immunisation with acellular and whole-cell pertussis vaccines: a systematic review","volume":"36","author":"J Patterson","year":"2018","journal-title":"Vaccine"},{"issue":"01","key":"ref43","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S1473-3099(17)30612-6","article-title":"A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2\/3, randomised controlled non-inferiority trial","volume":"18","author":"S Sricharoenchai","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"107047","DOI":"10.1016\/j.ijid.2024.107047","article-title":"Transplacental transfer of maternal antibodies following immunization with recombinant pertussis vaccines during pregnancy: real-world evidence","volume":"144","author":"S Chaithongwongwatthana","year":"2024","journal-title":"Int J Infect Dis"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0140-6736(22)02644-7","article-title":"Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, versus tetanus-diphtheria-acellular pertussis vaccine: a randomised, double-blind, phase 2b trial","volume":"401","author":"C Keech","year":"2023","journal-title":"Lancet"},{"issue":"03","key":"ref46","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3390\/vaccines8030523","article-title":"Manufacture of a stable lyophilized formulation of the live attenuated pertussis vaccine BPZE1","volume":"8","author":"M Thalen","year":"2020","journal-title":"Vaccines (Basel)"},{"issue":"09","key":"ref47","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3390\/toxins9090277","article-title":"Bordetella adenylate cyclase-hemolysin toxins","volume":"9","author":"N Guiso","year":"2017","journal-title":"Toxins (Basel)"},{"issue":"03","key":"ref48","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/14760584.2017.1276832","article-title":"Outer membrane vesicles: an attractive candidate for pertussis vaccines","volume":"16","author":"D F Hozbor","year":"2017","journal-title":"Expert Rev Vaccines"},{"issue":"06","key":"ref49","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41573-021-00163-y","article-title":"Emerging concepts in the science of vaccine adjuvants","volume":"20","author":"B Pulendran","year":"2021","journal-title":"Nat Rev Drug Discov"}],"container-title":["Seminars in Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2592-0735.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T22:49:52Z","timestamp":1749250192000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2592-0735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":43,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2025,6,6]]},"published-print":{"date-parts":[[2025,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2592-0735","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["1069-3424","1098-9048"],"issn-type":[{"value":"1069-3424","type":"print"},{"value":"1098-9048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}